MDGL Q1 2018 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$23,000

Operating Income

-$7M

Net Income

-$6M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$183M

Total Liabilities

$6M

Stockholders' Equity

$177M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$23,000	$0	—
Operating Income	-$7M	-$6M	-16.4%
Net Income	-$6M	-$6M	-6.1%